Core Insights - Myriad Genetics announced groundbreaking research on prenatal cell-free DNA screening at the Society for Maternal-Fetal Medicine Conference, highlighting the ability to conduct reliable tests as early as eight weeks of gestation [1][2] - The study received the Dru Carlson Memorial Award for Best Research in Ultrasound and Genetics, showcasing the significance of the findings in the field of prenatal genetic screening [1] Study Findings - The Prequel Prenatal Screen with AMPLIFY™ technology allows for accurate results at eight weeks of gestation, with an average fetal fraction (FF) of 12.5% and a no-call rate of less than 0.5% [1][3] - The study involved a multi-site approach where subjects provided samples at different gestational ages, confirming that the Prequel with AMPLIFY can deliver reliable results comparable to typical cfDNA screening at 10 weeks or later [3] Clinical Implications - The ability to assess risks for chromosomal disorders at eight weeks is a significant advancement, enabling earlier diagnostic testing options for patients, such as chorionic villus sampling at 10 weeks instead of the typical 15 weeks for amniocentesis [2] - This advancement empowers clinicians and patients to make informed decisions regarding prenatal care [2] Technology Overview - Myriad's Prequel Prenatal Screen with AMPLIFY technology is the first prenatal cfDNA screen available at eight weeks, increasing fetal fraction by an average of 2.3-fold [5] - The test assesses risks for various chromosomal conditions, including Down syndrome, Edwards syndrome, Patau syndrome, and sex chromosome abnormalities [5] Additional Presentations - Myriad Genetics will also present on detecting maternal mosaicism in fetal sex chromosome aneuploidy screening, aiming to improve positive predictive value (PPV) for sex chromosome anomalies [4]

SALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at the annual Society for Maternal-Fetal Medicine Conference (SMFM). The company's "Fetal fraction amplification enables accurate prenatal cell-free DNA (cfDNA) screening at eight weeks gestation" study was awarded SMFM's "Dru Carlson Memorial Award for Best Research in Ultrasound and Genetics." The study found that ...

Company Overview - Myriad Genetics, Inc. (MYGN) has launched a new educational website, Know More Sooner, aimed at providing comprehensive information about reproductive and prenatal genetic testing, which is expected to enhance the company's Prenatal business [1][5] - The company currently has a market capitalization of $937.2 million and has consistently surpassed earnings estimates in the past four quarters, with an average surprise of 247.73% [4] Stock Performance - Following the launch of the Know More Sooner website, MYGN shares increased by 3.9%, reaching $12.76 [2] - Over the past year, MYGN's shares have declined by 42.2%, in contrast to a 12.4% decline in the industry [10] Market Insights - A survey indicated that a majority of women expressed interest in prenatal screening once they understood the benefits of genetic testing, although 40% reported not being offered non-invasive prenatal testing (NIPT) [3] - The global non-invasive prenatal testing market was valued at $4.21 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 10.06% from 2024 to 2030, driven by increasing demand, collaborations, and improved reimbursement scenarios [7] Product Offerings - Myriad Genetics offers three genetic tests for pregnant individuals: the SneakPeek Gender Test, which predicts fetal sex with over 99% accuracy as early as six weeks; the Foresight Carrier Screen, which identifies risks for serious inherited conditions; and the Prequel Prenatal Screen, which assesses risks for various chromosomal conditions as early as eight weeks [6]

Core Insights - Myriad Genetics has launched a new educational website, "Know More Sooner," aimed at providing comprehensive information about reproductive and prenatal genetic testing [1][2] Group 1: Website Features and Purpose - The "Know More Sooner" website aims to educate users on the benefits of prenatal genetic testing, dispel myths, and provide guidance on screening locations and actions for high-risk results [2] - The site includes real-life patient stories to demonstrate how prenatal screening can assist parents in managing their pregnancies [2] Group 2: Survey Insights - A survey indicated that many women desire prenatal screening once they understand its benefits, yet 40% of respondents reported not being offered noninvasive prenatal testing (NIPT) [3] - The survey was conducted with 1,000 US-based individuals who identified as pregnant or recently pregnant [6] Group 3: Recommendations and Expert Opinions - The American College of Obstetricians and Gynecologists (ACOG) recommends that carrier and cfDNA screening be offered to all pregnant patients, regardless of ancestry, maternal age, or risk of chromosomal abnormalities [4] - Experts from Myriad Genetics emphasize the importance of understanding genetic testing benefits to help women make informed decisions during pregnancy [5] Group 4: Genetic Tests Offered - Myriad Genetics offers three genetic tests for pregnant individuals: - SneakPeek Gender Test, which predicts fetal sex as early as six weeks with over 99% accuracy [8] - Foresight Carrier Screen, identifying risks of passing down serious inherited conditions [8] - Prequel Prenatal Screen, assessing risks for various chromosomal conditions as early as eight weeks [8]

Core Insights - Myriad Genetics, Inc. announced a study showing that the use of an online screening tool and education significantly increased the completion rate of hereditary cancer testing among patients [1][2][3] Study Findings - The study evaluated the impact of MyGeneHistory®, an online patient screening tool, and a virtual education program on hereditary cancer testing completion rates [2][6] - Approximately 30% more patients were identified as meeting the guidelines for hereditary cancer testing (HCT) after implementing the online tool [8] - There was a 50% increase in the number of patients who met the guidelines and were offered HCT [8] - More than twice the number of patients completed HCT following the implementation of the new tools [8] Clinician Feedback - Clinicians reported increased confidence in administering hereditary cancer risk assessments, with 87% stating that the online screening and education tools helped them adhere to recommended standards of care [3] - Over 80% of providers believed the program assisted them in following ACOG guidelines for hereditary cancer risk assessment [3] Program Overview - Myriad's Breast Cancer Risk Assessment Program includes the MyRisk® with RiskScore® Hereditary Cancer Test and the MyGeneHistory online screening tool [5] - The program aims to improve patient access and education regarding genetic testing [4][5] Study Details - The study involved over 10,000 patients across five U.S. community obstetrics/gynecology practices, with an eight-week observation period followed by training on the online tools [6]

Core Insights - A study by Myriad Genetics demonstrated that the use of an online screening tool and patient education significantly increased the completion rate of hereditary cancer testing among patients [1][2][8] Group 1: Study Findings - The implementation of MyGeneHistory, an online patient screening tool, led to a 30% increase in the identification of patients meeting guidelines for hereditary cancer testing (HCT) [8] - There was a 50% increase in the number of patients who met the guidelines and were offered HCT [8] - More than twice the number of patients completed HCT after the introduction of the online tool and education program [8] Group 2: Clinical Impact - Clinicians reported increased confidence in administering hereditary cancer risk assessments, with 87% stating that the online tools helped them adhere to recommended standards of care [3] - Over 80% of providers believed the program assisted them in following ACOG guidelines for hereditary cancer risk assessment [3] Group 3: Program Details - Myriad's Breast Cancer Risk Assessment Program includes the MyRisk with RiskScore Hereditary Cancer Test and the MyGeneHistory online screening tool, which assesses if a patient meets medical guidelines for hereditary cancer testing [5] - The program also provides patient education on genetic testing and guidance on collecting family history related to certain cancers [5] Group 4: Study Overview - The study involved over 10,000 patients across five U.S. community obstetrics/gynecology practices, with an eight-week observation period followed by training on the online screening and education program [6]

SALT LAKE CITY, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced select unaudited preliminary results for the fourth quarter and full year ended December 31, 2024, and provided full year 2025 financial guidance. Select Preliminary Fourth Quarter and Full Year 2024 Financial ResultsThe company expects the following: Fourth quarter of 2024 total revenues to be between $209 million and $211 million, an increase of approxi ...

Myriad Genetics, Inc. (MYGN) recently announced an agreement with Hannah Storm, a nationally renowned sports broadcaster who recently revealed her battle with breast cancer. Under the agreement, Storm will act as an ambassador for the Myriad Genetics Breast Cancer Risk Assessment Program, which features the MyRisk with RiskScore Hereditary Cancer test.The latest collaboration with Storm will bolster the company’s Hereditary Cancer testing business. MYGN Stock’s Likely Trend Following the NewsMyriad Genetic’ ...

Company Announcement - Myriad Genetics announced a partnership with Hannah Storm, a renowned sports broadcaster, to promote the Myriad Genetics Breast Cancer Risk Assessment Program [1] - Hannah Storm will serve as an ambassador for the MyRisk with RiskScore Hereditary Cancer Test, the industry-leading hereditary cancer and polygenic risk prediction test [2] - The partnership aims to raise awareness about the importance of family health history in understanding cancer risks [2] Product Details - MyRisk with RiskScore evaluates 48 genes associated with hereditary cancer risk and provides a five-year and lifetime breast cancer risk assessment [6] - The test identifies genetic changes linked to increased cancer risk for 11 different cancers and combines this with family history and clinical factors like breast density [6] Awareness Campaign - Hannah Storm will share content on her social media platforms about the importance of knowing family health history and having conversations about hereditary cancers [5] - The campaign will encourage women to discuss their family health history with healthcare providers and consider preventive steps [5] Industry Impact - Myriad Genetics is a leader in genetic testing and precision medicine, focusing on advancing health and well-being through genetic insights [7] - The company develops genetic tests that assess disease risk, guide treatment decisions, and improve patient care while lowering healthcare costs [7] Personal Story - Hannah Storm was diagnosed with stage zero Ductal Carcinoma in Situ (DCIS) in January 2024, detected through a routine mammogram and subsequent tests [4] - She emphasizes the importance of genetic testing for early detection and understanding potential hereditary risks for her daughters [3]

News release updated to include the members of the management team speaking at the conference. SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, President and CEO, and Sam Raha, COO, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15, at 3:45pm PT (6:45pm ET). The presentation will be available through a live webcast in the investor rel ...